mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455

Abstract

Stimulation of the metabotropic glutamate receptor 4 (mGluR4) represents a promising new approach to the symptomatic treatment of the neurodegenerative disorder Parkinson's disease (PD). Preclinical models using both agonists and positive allosteric modulators of mGluR4 have demonstrated the potential for this receptor for the treatment of PD. The present article evaluates a recent patent filed by Addex Pharma S.A. claiming a novel series of mGluR4 positive allosteric modulators. Many of the examples disclosed are active at EC₅₀'s < 500 nM.

Keywords::

• Addex
• allosteric modulators
• mGluR4
• Parkinson's disease